“South Africa’s Department of Health has successfully rolled out Lenacapavir, a twice‑yearly injectable HIV prevention drug, with more than 55,000 people initiated across six provinces since June 2026. The program prioritizes pregnant and breastfeeding mothers, marking a major step toward reducing HIV transmission nationwide.”
South Africa has long been at the forefront of the global fight against HIV/AIDS. With one of the highest HIV prevalence rates in the world, the country has continuously sought innovative solutions to curb transmission and improve prevention. In September 2026, the Department of Health announced a landmark achievement: more than 55,000 individuals have been initiated on Lenacapavir, a revolutionary twice‑yearly injectable HIV prevention medication. This rollout, launched in June 2026, represents a significant leap forward in public health strategy and offers hope for millions vulnerable to HIV infection.
Background on Lenacapavir
Lenacapavir is a long‑acting antiretroviral drug administered every six months as pre‑exposure prophylaxis (PrEP). Unlike traditional daily oral PrEP regimens, Lenacapavir reduces the burden of adherence, making prevention more accessible and sustainable. The South African Health Products Regulatory Authority (SAHPRA) approved the drug earlier this year after rigorous clinical trials demonstrated its safety and efficacy.
Rollout Milestones
- Launch Date: June 5, 2026, by President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi.
- Facilities: 360 public health facilities across 24 districts in six provinces.
- Initiations: 55,123 individuals by September 7, 2026.
- Demographics: 71% female, with a majority being pregnant and breastfeeding mothers.
- Provincial Leaders: Gauteng leads with 26,357 initiations, followed by KwaZulu‑Natal (11,941), North West (4,479), Western Cape (4,446), Mpumalanga (4,294), and Eastern Cape (3,606).
Public Health Impact
The rollout addresses critical challenges in HIV prevention:
- Adherence: Daily oral PrEP often suffers from poor adherence; Lenacapavir’s twice‑yearly injection eliminates this barrier.
- Accessibility: By expanding to rural and urban facilities, the program ensures equitable access.
- Maternal Health: Prioritizing pregnant and breastfeeding mothers reduces mother‑to‑child transmission risks.
- Community Trust: Public awareness campaigns are building confidence in vaccines and prevention drugs, countering hesitancy.
Government Strategy
The government has set ambitious targets:
- 1 million initiations by end of 2027.
- 3 million initiations within three years. This strategy aligns with South Africa’s broader HIV prevention goals and global commitments to end AIDS as a public health threat by 2030.
Challenges Ahead
Despite the success, challenges remain:
- Supply Chain: Ensuring consistent availability of Lenacapavir across all provinces.
- Monitoring: Healthcare workers must track uptake, side effects, and patient safety.
- Equity: Rural areas may face slower rollout compared to urban centers.
- Sustainability: Funding and long‑term resource allocation will determine the program’s endurance.
Expert Perspectives
Public health experts hail the rollout as a “game‑changer” in HIV prevention. The World Health Organization has recommended long‑acting PrEP options as part of combination prevention strategies. South Africa’s adoption of Lenacapavir demonstrates leadership in implementing cutting‑edge solutions.
Conclusion
The initiation of over 55,000 individuals on Lenacapavir within three months underscores South Africa’s commitment to tackling HIV head‑on. By prioritizing vulnerable populations, leveraging innovative science, and mobilizing nationwide resources, the country is setting a precedent for global HIV prevention. While challenges remain, the momentum generated by this rollout offers renewed hope that South Africa can significantly reduce HIV transmission rates and move closer to achieving its elimination goals.
